User profiles for Romain-David Seban

Romain Seban

Institut Curie
Verified email at curie.fr
Cited by 981

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

RD Seban, L Mezquita, A Berenbaum, L Dercle… - European journal of …, 2020 - Springer
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …

18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 …

L Dercle, RD Seban, J Lazarovici… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for
the assessment of chemotherapy and targeted molecular agents. We investigated the …

Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging

A Peltier, RD Seban, I Buvat, FC Bidard… - Seminars in Cancer …, 2022 - Elsevier
Cancer-Associated Fibroblasts (CAFs) represent the most prominent component of the tumor
microenvironment (TME). Recent studies demonstrated that CAF are heterogeneous and …

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

RD Seban, JS Nemer, A Marabelle, R Yeh… - European journal of …, 2019 - Springer
Purpose An imaging-based stratification tool is needed to identify melanoma patients who
will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying …

Emerging and evolving concepts in cancer immunotherapy imaging

L Dercle, S Sun, RD Seban, A Mekki, R Sun, L Tselikas… - Radiology, 2023 - pubs.rsna.org
Criteria based on measurements of lesion diameter at CT have guided treatment with
historical therapies due to the strong association between tumor size and survival. Clinical …

Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4

RD Seban, A Moya-Plana, L Antonios, R Yeh… - European journal of …, 2020 - Springer
Purpose To compare the prognostic value of imaging biomarkers derived from a quantitative
analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or …

[HTML][HTML] Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy

…, C Massard, C Ferté, L Taihi, RD Seban… - European journal of …, 2016 - Elsevier
Background Drugs targeting programmed death receptor-1 (PD-1) and its ligand PD-L1
have shown activity in multiple malignancies. Considering their novel mechanism of action, …

Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo-or …

RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani… - Lung Cancer, 2021 - Elsevier
Objectives We aimed to compare the prognostic value of inflammatory biomarkers extracted
from pretreatment peripheral blood and [18F]-FDG PET for estimating outcomes in non-…

[HTML][HTML] Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line …

RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani… - Cancers, 2020 - mdpi.com
Background: We aimed to assess the clinical utility of a previously published score combining
the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment …

Early 18F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab

…, B Deau-Fischer, F Peyrade, RD Seban… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab
and pembrolizumab, are associated with high response rates in patients with relapsed or …